
Sign up to save your podcasts
Or


In this episode of Mind & Medicine, science journalist (AI generated) Julian Vance and neurologist Dr. Maya Lin (AI) examine the clinical realities behind blood-based biomarkers for Alzheimer’s disease. While non-invasive blood tests measuring plasma proteins like phosphorylated tau 217 (p-tau217) represent a major technical milestone in neurology, public discussion often overlooks critical diagnostic nuance.
This episode breaks down what plasma biomarkers actually measure, the fundamental difference between detecting biological pathology and diagnosing clinical dementia, and why confounding physical factors like kidney function matter. Dr. Lin details the consensus guidelines established by organizations such as the Alzheimer’s Association, explaining why these tests are strictly recommended for patients aged 55 and older with objective cognitive impairment rather than healthy, asymptomatic populations.
From the publisher's feed